ARS PHARMACEUTICALS INC (SPRY)
US82835W1080 - Common Stock
| MRQ (2024-9-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 39.66M | 70.97M | 210.50M | 254.00M | 386.60M | |||
| Marketable Securities | 164.97M | 157.39M | 63.90M | N/A | N/A | |||
| Receivables | 1.24M | N/A | N/A | N/A | N/A | |||
| Inventories | 715.00K | N/A | N/A | N/A | N/A | |||
| Other Current Assets | 2.21M | 3.37M | 3.30M | 7.40M | 4.10M | |||
| Total Current Assets | 208.79M | 231.73M | 277.70M | 261.50M | 390.70M | |||
| Non-Current Assets | ||||||||
| PPE Net | 935.00K | 824.00K | 800.00K | 6.90M | 3.80M | |||
| Investments And Advances | N/A | N/A | N/A | 64.80M | N/A | |||
| Intangibles | 7.50M | N/A | N/A | N/A | N/A | |||
| Other Non-Current Assets | 377.00K | 638.00K | 3.00M | 300.00K | 400.00K | |||
| Total Non-Current Assets | 8.81M | 1.46M | 3.70M | 72.00M | 4.10M | |||
| TOTAL ASSETS | 217.60M | 233.19M | 281.40M | 333.50M | 394.80M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 800.00K | |||
| Current Portion Of LT Debt. | N/A | N/A | 0.00 | N/A | N/A | |||
| Accrued Expenses | 4.96M | 916.00K | 1.70M | 12.80M | 6.20M | |||
| Accounts Payable | 11.66M | 1.48M | 3.50M | 2.10M | 2.60M | |||
| Other Current Liabilities | N/A | 0.00 | 300.00K | N/A | N/A | |||
| Total Current Liabilities | 16.62M | 2.39M | 5.40M | 14.90M | 9.60M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 0.00 | 37.00K | 3.10M | 4.80M | 2.30M | |||
| Total Non-Current Liabilities | 0.00 | 37.00K | 3.10M | 4.80M | 2.30M | |||
| TOTAL LIABILITIES | 16.62M | 2.43M | 8.50M | 19.70M | 11.90M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -173.24M | -131.30M | -76.90M | -186.20M | -96.70M | |||
| Additional Paid In Capital | 373.87M | 362.00M | 349.40M | 500.30M | 479.60M | |||
| Common Shares | 10.00K | 10.00K | 0.00 | 0.00 | 0.00 | |||
| Other Shareholders' Equity | 339.00K | 49.00K | 400.00K | -300.00K | N/A | |||
| Shares Outstanding | 97.15M | 96.41M | 93.90M | 35.10M | 34.70M | |||
| Tangible Book Value per Share | 1.99 | 2.39 | 2.91 | 8.94 | 11.03 | |||
| Total Shareholders' Equity | 200.98M | 230.76M | 272.90M | 313.80M | 382.90M | |||
| TOTAL LIABILITIES AND EQUITY | 217.60M | 233.19M | 281.40M | 333.50M | 394.80M | |||
| Statistics | ||||||||
| Current Ratio | 12.56 | 96.92 | 51.43 | 17.55 | 40.70 | |||
| Return On Assets (ROA) | -22.57% | -23.31% | -12.32% | -26.83% | -8.35% | |||
| Return On Equity (ROE) | -24.43% | -23.56% | -12.71% | -28.51% | -8.61% | |||
All data in USD , ROIC based on taxRate of 0.21